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Abstract
Hashimoto's encephalopathy (HE), also known as steroid-responsive encephalopathy, is associated with
autoimmune-mediated thyroiditis. Onset is typically gradual often with evolution over the course of
months. Characteristic symptoms include impaired concentration and memory, delusions, hallucinations,
personality changes, incoordination, tremor, hemiparesis, seizures, and speech difficulties. Diagnosis is
predicated upon discovery of elevated anti-thyroid antibodies, specifically anti-thyroid peroxidase (TPO) or
anti-M antibodies. Some patients may also present with subclinical hypothyroidism but many are euthyroid.
Of note, neither thyroid function tests or antibody titers correlate with disease severity. Other common
laboratory findings include elevations in sedimentation rate, liver enzymes, and cerebrospinal fluid (CSF)
protein. Radiological work-up, including cerebral angiography, is often normal. Successful treatment
includes administration of steroids and/or intravenous immunoglobulin (IVIg) or plasmapheresis. We
describe a case of a 74-year-old male who presented for evaluation of abrupt onset confusion ultimately
determined to be a consequence of autoimmune-mediated thyroiditis.
Categories: Endocrinology/Diabetes/Metabolism, Medical Education, Neurology
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Introduction
Hashimoto's encephalopathy (HE), or steroid-responsive encephalopathy, is a disorder associated with
autoimmune-mediated thyroiditis. It affects both the nervous and endocrine systems [1]. It is characterized
by myoclonus, seizures, and confusion with often fluctuating levels of consciousness. The condition may
also be associated with paranoid delusions and hallucinations. Unfortunately, the cause remains unknown
[2]. Available literature suggests a pathological inflammatory response as a central feature in the evolution
of the disease. Still, a clear association between encephalopathy and Hashimoto's thyroiditis (HT) has yet to
be established. It is well established that corticosteroid or other immunosuppressive therapies (e.g. IVIg,
plasmapheresis) afford significant improvement, or complete resolution, of symptoms. Its course is variable
and may be self-limited without treatment, progressive without treatment, resolve with treatment, or follow
a relapsing-remitting course in spite of treatment.
Case Presentation
A 74-year-old male with remote history of left frontal lobe stroke, uncontrolled insulin-dependent diabetes
mellitus, coronary artery disease, atrial fibrillation, congestive heart failure, and pseudogout presented for
evaluation of waxing and waning confusion that began 24 hours prior to arrival. Prior to evaluation by our
Neurology service, he was found to have a urinary tract infection (UTI) and started on Levaquin. A non-
contrast computed tomography (NCCT) scan of the head revealed chronic left frontal encephalomalacia
(Figure 1).
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FIGURE 1: NCCT scan of head showing hypodensity in left frontal lobe
representing chronic encephalomalacia.
NCCT = non-contrast computed tomography 
Subsequent MRI brain showed an acute infarct in the right splenial region of the corpus callosum on
diffusion-weighted imaging (Figure 2).
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FIGURE 2: MR axial DWI sequence showing focus of restricted diffusion
in the right splenial region of the corpus callosum.
MR = magnetic resonance
DWI = diffusion weight imaging 
This infarct was new when compared to an MRI brain that was performed outpatient one week prior to
presentation to our emergency department (image unavailable). He had reportedly experienced progressive
cognitive decline over the six months preceding presentation.
The finding in Figure 1 was also confirmed via MRI fluid-attenuated inversion recovery (FLAIR) sequence
(Figure 3).
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FIGURE 3: MR axial FLAIR sequence showing increased signal in left
frontal lobe representing chronic encephalomalacia.
MR = magnetic resonance
FLAIR = fluid-attenuated inversion recovery 
Additional tests were performed to further characterize his persistent stupor. Conventional angiogram was
without evidence of vasculitis. Contrast-enhanced CT of the chest showed asymmetric enlargement of the
thyroid with leftward sub-sternal extension; there was no sign of malignancy. Contrast-enhanced CT of the
abdomen and pelvis was also negative for malignancy. Electroencephalogram was without evidence of
epileptiform discharge or seizure activity. A lumbar puncture showed no evidence of pleocytosis but did
reveal elevated protein (63mg/dL; normal range 15-45) and IgG index (6.4mg/dL; normal 0.0-6.0). Due to
findings on CT chest, NCCT of the soft tissues of the neck was performed which revealed enlarged left
thyroid lobe (Figure 4). 
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FIGURE 4: NCCT of the soft tissues of the neck showing prominent left
thyroid lobe.
NCCT = non-contrast computed tomography
Other notable labs during hospitalization included persistently elevated sedimentation rate with a peak of
127 mm/hr (normal range 0-20), white blood cell count with a peak of 16.3K/µL (normal range 4.5-11.0), C-
reactive protein of 10 mg/L (normal range <10), negative blood cultures, total T3 0.3 ng/mL (normal range
0.9-2.44), free T3 1.2 pg/ml (normal range 3.7-4.2), free T4 0.9 ng/dl (normal range 1.3-2.8), thyroid
stimulating hormone (TSH) 0.233 mIU/ml (normal range 0.5-1.5), thyroid peroxidase antibody titer 20.1
lU/ml (normal range <2). A paraneoplastic panel and encephalitis screen for herpes simplex virus (HSV) and
cytomegalovirus (CMV) were unremarkable.
The elevated thyroid peroxidase antibody titer with concomitant elevation of inflammatory markers
suggested a probable diagnosis of HE. 
High-dose steroid infusion was initiated via intravenous solumedrol, 500mg, twice daily for three days. He
also received IVIg infusion (0.4mg/kg) once daily for five days. 
Following treatment, his mental status improved rapidly with eventual return to baseline. 
Discussion
A detailed understanding of the immunopathology underlying HE is paramount in reliable diagnosis.
Presently, the mechanism that promotes formation of anti-thyroid antibodies is unknown. Regardless, these
antibodies are considered pathologic and may develop as a consequence of cross targeting of foreign
antigens invading the body. Still, there is no general consensus in current medical literature [3]. The link
between encephalopathy and HT is not yet known since there is no evidence that anti-thyroid antibodies are
harmful to neurons [4]. Further, a significant number of encephalopathic patients with antithyroid
antibodies are euthyroid. Hence, a more accurate name for this condition has been coined: steroid-
responsive encephalopathy associated with autoimmune thyroiditis (SREAT). The type and severity of
symptoms vary in those affected by this disease [5]. The common feature in diagnosis of patients with SREAT
is the presence of anti-thyroid antibodies, specifically anti-TPO or anti-M antibodies. However, these
antibodies have been noted to be highly prevalent in normal subjects. In one study, the prevalence of high
anti-TPO antibody concentrations was 11% in euthyroid young adults, 23% in euthyroid women >60 years,
and 67% in older women with hypothyroidism [4].
Symptoms
The most common presenting symptom is abrupt confusion with altered level of consciousness but it may be
insidious. Some experience lethargy, visual hallucinations, and fluctuating confusion that may eventually
lead to dementia [6]. In extreme cases, lethargy can progress to coma [7]. Non-cognitive symptoms of
tremor, myoclonus, and seizures may also occur. Still, encephalopathy is the most common symptom. The
classic clinical picture is characterized by a decline in cognitive ability with impairment in orientation, level
of consciousness, and attention. Associated symptoms include poor appetite, hyperreflexia, seizures,
dysarthria, and ataxia. Other attributable, or pathognomonic, symptoms are difficult to identify due to the
rare nature of the disorder. Prognostication is difficult owing to the fact that a subset of patients will
experience a relapsing-remitting course in spite of treatment [8]. Anxiety, depression, hypersomnia, or
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difficulty initiating sleep can be the initial presenting symptom [9]. Depression, anxiety, social withdrawal,
and emotional lability as sole symptoms have also been reported [10].
Diagnosis
The diagnosis of this disorder is based on specialized clinical tests, history, and identification of
characteristic clinical signs and symptoms. Variable presentations make an already difficult diagnosis even
more difficult. A detectable level of anti-thyroid antibodies must be present for diagnosis [10]. If high serum
levels of these antibodies are found, cerebrospinal fluid should also be evaluated for elevated protein (a
nonspecific marker of inflammation that can be observed in patients with underlying endocrine
abnormalities). Electroencephalography may detect the presence of subclinical seizure activity or
generalized slowing related to encephalopathy. MRI brain is useful to eliminate the possibility of other
structural causes of encephalopathy [9].
Treatment
Corticosteroid administration is crucial to establish steroid responsiveness by nonspecifically targeting
inflammation including that originating within the central nervous system. An optimal dose of steroids has
yet to be established but it is presumed to vary with the severity of the condition. Initially, the general
consensus is that high doses of corticosteroids should be used with subsequent taper after the desired result
is achieved. High corticosteroid doses over a prolonged period have considerable side effects. Intravenous
immune globulin or plasmapheresis may also be used to neutralize circulating autoantibodies [11]. Typically,
symptoms are either significantly improved or resolve within a few months of treatment [11].
Conclusions
A high index of suspicion is necessary for reliable identification and diagnosis of this rare and disabling, but
treatable, condition. Routine ordering of anti-thyroid antibodies (i.e. anti-TPO and anti-M) may not be cost
effective in the workup of the frequently encountered encephalopathic patient, especially in cases where
thyroid function is found to be normal. However, if a patient does not return to baseline in a timely fashion
after all potential precipitating factors have been addressed, HE (or SREAT) should be considered.
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